1-2 of 2
Leandro Riera
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

90 Y-Ibritumomab Treatment for Relapsed and/or Refractory B Cell Type Non-Hodgkin’s Lymphoma. Multiinstitutional Argentinian Study.

Roberto Cacchione, MD, Juan Dupont, MD, Jorge Milone, MD, Javier Bordone, MD, Guy Garay, MD, Maria Ardaiz, MD, Miguel Castro-Rios, MD, Virginia Prates, MD, Alfredo Basso, MD, Marcelo Iabstrebner, MD, Graciela Avila, MD, Alicia Diaz, MD, Daniel Argentieri, MD, Silvia Rudoy, MD, Alicia Trouboul, MD, Luis Palmer, MD, Gonzalo Pombo, MD, Silvina Rappaciotti, MD, Pedro Negri, MD, Diana Lafalse, MD, Leandro Riera, MD, Miguel de Tezanos-Pinto, MD, Dardo Riveros, MD, Mario Brown Arnold, MD, Antonio Carrasco, MD, Fernando Bezares, MD
Journal: Blood
Blood (2007) 110 (11): 4484.
https://doi.org/10.1182/blood.V110.11.4484.4484
Published: 2007
Journal Articles

A Phase 2 Study of 90 Y-Ibritumomab Tiuxetan ( 90 Y-Zevalin®) in Relapsed/Refractory Non-Hodgkin’s Lymphoma: Preliminary Report of the Argentinean Cooperative Group.

Roberto E. Cacchione, MD, Jorge Milone, Javier Bordone, Juan Dupont, Gustavo Milone, Dardo Riveros, Pedro Negri, María Ardaiz, Leandro Riera, Maria Cecilia Foncuberta, Fernando Bezares
Journal: Blood
Blood (2006) 108 (11): 4688.
https://doi.org/10.1182/blood.V108.11.4688.4688
Published: 2006